C
Clarence E. Davis
Researcher at University of North Carolina at Chapel Hill
Publications - 93
Citations - 21128
Clarence E. Davis is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Population & Risk factor. The author has an hindex of 44, co-authored 93 publications receiving 20581 citations. Previous affiliations of Clarence E. Davis include National Institutes of Health & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
TL;DR: The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
Journal ArticleDOI
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
TL;DR: The angiotensin-converting--enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction.
Journal ArticleDOI
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study
Shih-Jen Hwang,Christie M. Ballantyne,A. Richey Sharrett,L. C. Smith,Clarence E. Davis,Antonio M. Gotto,Eric Boerwinkle +6 more
TL;DR: Results of logistic regression analyses indicated that the relationship of ICAM-1 and E-selectin with CHD and CAA was independent of other known CHD risk factors and was most pronounced in the highest quartile.
Journal ArticleDOI
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe,Robert M. Bilder,Sonia M. Davis,Philip D. Harvey,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,George Capuano,T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Clarence E. Davis,John K. Hsiao,Jeffrey A. Lieberman +16 more
TL;DR: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.
Journal ArticleDOI
Physical activity and cardiovascular health
Russell V. Luepker,Suzanne Bennett Johnson,L. Breslow,A. V. Chobanian,Clarence E. Davis,B. R. Duling,Shiriki K. Kumanyika,R. M. Lauer,P. Lawson,P. E. McBride,S. Oparil,Ronald J. Prineas,R. L. Washington +12 more
TL;DR: All Americans should engage in regular physical activity at a level appropriate to their capacity, needs, and interest, and children and adults alike should set a goal of accumulating at least 30 minutes of moderate-intensity physical activity on most, and preferably, all days of the week.